JP2019533016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533016A5 JP2019533016A5 JP2019538106A JP2019538106A JP2019533016A5 JP 2019533016 A5 JP2019533016 A5 JP 2019533016A5 JP 2019538106 A JP2019538106 A JP 2019538106A JP 2019538106 A JP2019538106 A JP 2019538106A JP 2019533016 A5 JP2019533016 A5 JP 2019533016A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- formula
- alkyl
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 172
- 150000001875 compounds Chemical class 0.000 claims description 121
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 54
- 208000017442 Retinal disease Diseases 0.000 claims description 48
- 206010038923 Retinopathy Diseases 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- 239000003937 drug carrier Substances 0.000 claims description 36
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 36
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 238000009472 formulation Methods 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 28
- 229920000858 Cyclodextrin Polymers 0.000 claims description 24
- -1 trifluoroalkoxy Chemical group 0.000 claims description 23
- 239000001116 FEMA 4028 Substances 0.000 claims description 16
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 16
- 229960004853 betadex Drugs 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 230000000202 analgesic effect Effects 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 11
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 239000000661 sodium alginate Substances 0.000 claims description 10
- 235000010413 sodium alginate Nutrition 0.000 claims description 10
- 229940005550 sodium alginate Drugs 0.000 claims description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 206010010741 Conjunctivitis Diseases 0.000 claims description 7
- 229920002148 Gellan gum Polymers 0.000 claims description 7
- 235000010492 gellan gum Nutrition 0.000 claims description 7
- 239000000216 gellan gum Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 6
- 229920002675 Polyoxyl Polymers 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 5
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 5
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 5
- 239000004327 boric acid Substances 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 201000001948 hypertensive retinopathy Diseases 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 claims description 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 4
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 206010015943 Eye inflammation Diseases 0.000 claims description 3
- 208000001344 Macular Edema Diseases 0.000 claims description 3
- 206010025415 Macular oedema Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 201000010230 macular retinal edema Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229920000570 polyether Polymers 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 2
- 206010015958 Eye pain Diseases 0.000 claims 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 210000001957 retinal vein Anatomy 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000004561 lacrimal apparatus Anatomy 0.000 claims 1
- 238000000520 microinjection Methods 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 49
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
- 229920000053 polysorbate 80 Polymers 0.000 description 9
- 239000006196 drop Substances 0.000 description 8
- 239000002105 nanoparticle Substances 0.000 description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 6
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400955P | 2016-09-28 | 2016-09-28 | |
| US62/400,955 | 2016-09-28 | ||
| US201762564595P | 2017-09-28 | 2017-09-28 | |
| PCT/US2017/054051 WO2018064354A1 (en) | 2016-09-28 | 2017-09-28 | Compositions and methods for treating ophthalmic conditions |
| US62/564,595 | 2017-09-28 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533016A JP2019533016A (ja) | 2019-11-14 |
| JP2019533016A5 true JP2019533016A5 (cg-RX-API-DMAC10.html) | 2020-11-12 |
| JP7030345B2 JP7030345B2 (ja) | 2022-03-07 |
Family
ID=61760847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538106A Active JP7030345B2 (ja) | 2016-09-28 | 2017-09-28 | 眼の状態を処置する組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11510931B2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7030345B2 (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017336765B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112019006160A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3038528A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2019003623A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018064354A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CN108135737B (zh) | 2015-06-06 | 2021-11-05 | 拨云生物医药科技(广州)有限公司 | 用于治疗翼状胬肉的组合物和方法 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| CN109152774A (zh) | 2016-05-09 | 2019-01-04 | 奥尔德拉医疗公司 | 眼部炎性病症和疾病的组合治疗 |
| BR112018074450A2 (pt) | 2016-06-02 | 2019-03-19 | Cloudbreak Therapeutics, Llc | composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma |
| WO2018064354A1 (en) | 2016-09-28 | 2018-04-05 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| CA3077033A1 (en) * | 2017-09-28 | 2019-04-04 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| WO2020018498A1 (en) * | 2018-07-16 | 2020-01-23 | Aldeyra Therapeutics, Inc. | Cyclodextrin formulations |
| CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| WO2020047197A1 (en) * | 2018-08-29 | 2020-03-05 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| CN113056353B (zh) | 2018-09-25 | 2022-11-01 | 奥尔德拉医疗公司 | 用于治疗干眼病的调配物 |
| ES2990204T3 (es) * | 2018-10-19 | 2024-11-29 | Univ Minnesota | Procedimientos de aislamiento y utilización de la membrana de Descemet y composiciones que incluyen membrana de Descemet aislada |
| KR102151051B1 (ko) * | 2019-01-10 | 2020-09-02 | 고려대학교 산학협력단 | 당뇨병성 백내장 치료 또는 예방용 조성물 |
| US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| BR112021026662A2 (pt) * | 2019-09-10 | 2022-04-12 | Cloudbreak Therapeutics Llc | Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2022031830A1 (en) * | 2020-08-04 | 2022-02-10 | Harrow Ip Llc | Antibacterial compositions and methods for fabricating thereof |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| EP4288151A4 (en) | 2021-02-03 | 2025-01-01 | ADS Therapeutics LLC | Topical ophthalmological compositions |
| US11213551B1 (en) | 2021-04-05 | 2022-01-04 | Korb Research, Llc. | Ocular treatment compositions and methods of use thereof |
| RS64402B1 (sr) * | 2021-05-24 | 2023-08-31 | Medicon Pharmaceuticals Inc | Lečenje bola povezanog sa dijabetičkom perifernom neuropatijom |
| PL4114403T3 (pl) | 2021-05-24 | 2023-10-09 | Medicon Pharmaceuticals, Inc. | Leczenie bólu neuropatycznego towarzyszącego neuropatii obwodowej indukowanej przez chemioterapię |
| AU2023273823A1 (en) * | 2022-05-18 | 2024-12-05 | Glaukos Corporation | Novel applications of zwitterions in ophthalmic topical cream compositions and preparations |
| WO2025111079A1 (en) | 2023-11-21 | 2025-05-30 | Medicon Pharmaceuticals, Inc. | Isomers of phosphosulindac |
| WO2025176750A1 (en) | 2024-02-23 | 2025-08-28 | Heinrich-Heine-Universität Düsseldorf | Dual targeting in a new class of active ingredients |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US4309566A (en) | 1979-11-05 | 1982-01-05 | Fmc Corporation | Plant regulator |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| AU684950B2 (en) | 1994-05-06 | 1998-01-08 | Alcon Laboratories, Inc. | Use of vitamin E tocopheryl derivatives in ophthalmic compositions |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| RU26988U1 (ru) | 2002-05-06 | 2003-01-10 | Закрытое акционерное общество "ДУКС-ЛИЗИНГ" | Кондуктор для сверления отверстий |
| US20080153746A1 (en) | 2004-04-06 | 2008-06-26 | Transmolecular, Inc. | Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers |
| CN1976692B (zh) | 2004-06-23 | 2011-05-25 | 矫正诊疗公司 | 用视黄基衍生物治疗眼部疾病的方法和组合物 |
| US20070299124A1 (en) | 2006-01-25 | 2007-12-27 | Ousler George W Iii | Formulations and methods for treating dry eye |
| CN101754748A (zh) | 2007-05-24 | 2010-06-23 | 阿西克斯医疗公司 | 治疗干眼症的制剂和方法 |
| WO2009023631A1 (en) | 2007-08-10 | 2009-02-19 | Basil Rigas | Anti-inflammatory compounds and uses thereof |
| US20120295979A1 (en) | 2011-05-03 | 2012-11-22 | Florida Atlantic University | Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress |
| WO2013130625A1 (en) * | 2012-02-27 | 2013-09-06 | Basil Rigas | Phospho-ester derivatives and uses thereof |
| CA2885740A1 (en) | 2012-09-21 | 2014-03-27 | Basil Rigas | Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof |
| US20160051526A1 (en) | 2013-04-09 | 2016-02-25 | Cresset Biomolecular Discovery Ltd | The Local Treatment of Inflammatory Ophthalmic Disorders |
| WO2018064354A1 (en) | 2016-09-28 | 2018-04-05 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| CA3077033A1 (en) | 2017-09-28 | 2019-04-04 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
-
2017
- 2017-09-28 WO PCT/US2017/054051 patent/WO2018064354A1/en not_active Ceased
- 2017-09-28 CA CA3038528A patent/CA3038528A1/en active Pending
- 2017-09-28 BR BR112019006160A patent/BR112019006160A2/pt not_active Application Discontinuation
- 2017-09-28 MX MX2019003623A patent/MX2019003623A/es unknown
- 2017-09-28 JP JP2019538106A patent/JP7030345B2/ja active Active
- 2017-09-28 AU AU2017336765A patent/AU2017336765B2/en active Active
- 2017-09-28 US US16/337,734 patent/US11510931B2/en active Active
-
2022
- 2022-11-08 US US18/053,503 patent/US20230293557A1/en not_active Abandoned
-
2023
- 2023-09-07 AU AU2023226711A patent/AU2023226711A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9023790B2 (en) | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin | |
| US12383565B2 (en) | Treatment of diabetic retinopathy with ophthalmic compositions | |
| JP2020536067A5 (cg-RX-API-DMAC10.html) | ||
| US20180169079A1 (en) | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound | |
| JP2015509528A (ja) | ピロキシカムまたはその薬学的に許容される塩とヒアルロン酸またはその薬学的に許容される塩とを含む安定な液状の医薬組成物およびその製造方法 | |
| US20240139204A1 (en) | Pharmaceutical liquid compositions of meloxicam | |
| US20240058358A1 (en) | Ph stabilized topical ophthlamic compositions | |
| EP4055005A1 (en) | Liquid melphalan composition | |
| WO2019097413A1 (en) | Stable non-aqueous pharmaceutical compositions | |
| TW202519198A (zh) | 治療糖尿病黃斑水腫的方法 | |
| MXPA04009037A (es) | Formulacion de eplerenona de almacenamiento estable. | |
| WO2025094002A1 (en) | Lurbinectedin formulation | |
| JP2025522933A (ja) | メルファランを含む安定した液体医薬組成物 | |
| HK1140130A (en) | Solubilized formulation of docetaxel without tween 80 |